Dilated cardiomyopathy

Research output: Contribution to journalReview article

268 Citations (Scopus)

Abstract

Dilated cardiomyopathy is characterised by left ventricular dilation that is associated with systolic dysfunction. Diastolic dysfunction and impaired right ventricular function can develop. Affected individuals are at risk of left or right ventricular failure, or both. Heart failure symptoms can be exercise-induced or persistent at rest. Many patients are asymptomatic. Chronically treated patients sometimes present acutely with decompensated heart failure. Other life-threatening risks are ventricular arrhythmias and atrioventricular block, syncope, and sudden death. Genetic inheritance arises in 30-48% of patients, and inflammatory disorders such as myocarditis or toxic effects from medications, alcohol, or illicit drugs also result in dilated cardiomyopathy. Genes that cause dilated cardiomyopathy generally encode cytoskeletal and sarcomeric (contractile apparatus) proteins, although disturbance of calcium homeostasis also seems to be important. In children, disrupted mitochondrial function and metabolic abnormalities have a causal role. Treatments focus on improvement of cardiac efficiency and reduction of mechanical stress. Arrhythmia therapy and prevention of sudden death continue to be mainstays of treatment. Despite progress over the past 10 years, outcomes need to be improved.

Original languageEnglish (US)
Pages (from-to)752-762
Number of pages11
JournalThe Lancet
Volume375
Issue number9716
DOIs
StatePublished - Mar 1 2010
Externally publishedYes

Fingerprint

Dilated Cardiomyopathy
Sudden Death
Cardiac Arrhythmias
Heart Failure
Contractile Proteins
Right Ventricular Function
Mechanical Stress
Atrioventricular Block
Poisons
Myocarditis
Syncope
Street Drugs
Dilatation
Homeostasis
Therapeutics
Alcohols
Exercise
Calcium
Genes

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Dilated cardiomyopathy. / Jefferies, John; Towbin, Jeffrey.

In: The Lancet, Vol. 375, No. 9716, 01.03.2010, p. 752-762.

Research output: Contribution to journalReview article

Jefferies, John ; Towbin, Jeffrey. / Dilated cardiomyopathy. In: The Lancet. 2010 ; Vol. 375, No. 9716. pp. 752-762.
@article{1cece77d4ce642c4af283b937c77563d,
title = "Dilated cardiomyopathy",
abstract = "Dilated cardiomyopathy is characterised by left ventricular dilation that is associated with systolic dysfunction. Diastolic dysfunction and impaired right ventricular function can develop. Affected individuals are at risk of left or right ventricular failure, or both. Heart failure symptoms can be exercise-induced or persistent at rest. Many patients are asymptomatic. Chronically treated patients sometimes present acutely with decompensated heart failure. Other life-threatening risks are ventricular arrhythmias and atrioventricular block, syncope, and sudden death. Genetic inheritance arises in 30-48{\%} of patients, and inflammatory disorders such as myocarditis or toxic effects from medications, alcohol, or illicit drugs also result in dilated cardiomyopathy. Genes that cause dilated cardiomyopathy generally encode cytoskeletal and sarcomeric (contractile apparatus) proteins, although disturbance of calcium homeostasis also seems to be important. In children, disrupted mitochondrial function and metabolic abnormalities have a causal role. Treatments focus on improvement of cardiac efficiency and reduction of mechanical stress. Arrhythmia therapy and prevention of sudden death continue to be mainstays of treatment. Despite progress over the past 10 years, outcomes need to be improved.",
author = "John Jefferies and Jeffrey Towbin",
year = "2010",
month = "3",
day = "1",
doi = "10.1016/S0140-6736(09)62023-7",
language = "English (US)",
volume = "375",
pages = "752--762",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9716",

}

TY - JOUR

T1 - Dilated cardiomyopathy

AU - Jefferies, John

AU - Towbin, Jeffrey

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Dilated cardiomyopathy is characterised by left ventricular dilation that is associated with systolic dysfunction. Diastolic dysfunction and impaired right ventricular function can develop. Affected individuals are at risk of left or right ventricular failure, or both. Heart failure symptoms can be exercise-induced or persistent at rest. Many patients are asymptomatic. Chronically treated patients sometimes present acutely with decompensated heart failure. Other life-threatening risks are ventricular arrhythmias and atrioventricular block, syncope, and sudden death. Genetic inheritance arises in 30-48% of patients, and inflammatory disorders such as myocarditis or toxic effects from medications, alcohol, or illicit drugs also result in dilated cardiomyopathy. Genes that cause dilated cardiomyopathy generally encode cytoskeletal and sarcomeric (contractile apparatus) proteins, although disturbance of calcium homeostasis also seems to be important. In children, disrupted mitochondrial function and metabolic abnormalities have a causal role. Treatments focus on improvement of cardiac efficiency and reduction of mechanical stress. Arrhythmia therapy and prevention of sudden death continue to be mainstays of treatment. Despite progress over the past 10 years, outcomes need to be improved.

AB - Dilated cardiomyopathy is characterised by left ventricular dilation that is associated with systolic dysfunction. Diastolic dysfunction and impaired right ventricular function can develop. Affected individuals are at risk of left or right ventricular failure, or both. Heart failure symptoms can be exercise-induced or persistent at rest. Many patients are asymptomatic. Chronically treated patients sometimes present acutely with decompensated heart failure. Other life-threatening risks are ventricular arrhythmias and atrioventricular block, syncope, and sudden death. Genetic inheritance arises in 30-48% of patients, and inflammatory disorders such as myocarditis or toxic effects from medications, alcohol, or illicit drugs also result in dilated cardiomyopathy. Genes that cause dilated cardiomyopathy generally encode cytoskeletal and sarcomeric (contractile apparatus) proteins, although disturbance of calcium homeostasis also seems to be important. In children, disrupted mitochondrial function and metabolic abnormalities have a causal role. Treatments focus on improvement of cardiac efficiency and reduction of mechanical stress. Arrhythmia therapy and prevention of sudden death continue to be mainstays of treatment. Despite progress over the past 10 years, outcomes need to be improved.

UR - http://www.scopus.com/inward/record.url?scp=77249109399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77249109399&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(09)62023-7

DO - 10.1016/S0140-6736(09)62023-7

M3 - Review article

VL - 375

SP - 752

EP - 762

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9716

ER -